Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?

Bibliographic Details
Title:	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
Authors:	Gianluca Perego, Antonio Ghidini, Andrea Luciani, Fausto Petrelli
Source:	Human Vaccines & Immunotherapeutics, Vol 17, Iss 12, Pp 5575-5578 (2021)
Publisher Information:	Taylor & Francis Group, 2021.
Publication Year:	2021
Collection:	LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology
Subject Terms:	immunoconjugates, older population, immunotherapy, monoclonal antibody, efficacy, toxicity, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
More Details:	Immunotherapeutic drugs and target therapies have represented an epochal change in treating cancer patients. They represent an attractive option in oncologists’ armamentarium, particularly if we consider the optimal balance between efficacy and toxicity. As a step forward, immuno- and target-therapies have merged intending to improve efficacy: antibody-drug conjugates ensure the perfect combination. They allow the delivery of large amounts of drugs to the target with a limited ‘off-target’ effect and a low rate of adverse events. These aspects could make immunoconjugates palatable as the first choice for fragile patients, but solid evidence does not exist on the use of these drugs in this population type, especially older people.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	2164-5515 2164-554X 21645515 27363694
Relation:	https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X
DOI:	10.1080/21645515.2021.1999711
Access URL:	https://doaj.org/article/3da1b103f8444b5eace27363694298c8
Accession Number:	edsdoj.3da1b103f8444b5eace27363694298c8
Database:	Directory of Open Access Journals

More Details
ISSN:	21645515 2164554X 27363694
DOI:	10.1080/21645515.2021.1999711
Published in:	Human Vaccines & Immunotherapeutics
Language:	English